Cargando…
Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body
[Image: see text] In this study, umbelliferone and α-cyclodextrin host molecules have been mixed up through a coprecipitation method to prepare a supramolecular complex to provide physical insights into the formation and stability of the inclusion complex (IC). The prepared hybrid was characterized...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689913/ https://www.ncbi.nlm.nih.gov/pubmed/33251458 http://dx.doi.org/10.1021/acsomega.0c04716 |
_version_ | 1783613959563116544 |
---|---|
author | Roy, Niloy Ghosh, Biswajit Roy, Debadrita Bhaumik, Biswajit Roy, Mahendra Nath |
author_facet | Roy, Niloy Ghosh, Biswajit Roy, Debadrita Bhaumik, Biswajit Roy, Mahendra Nath |
author_sort | Roy, Niloy |
collection | PubMed |
description | [Image: see text] In this study, umbelliferone and α-cyclodextrin host molecules have been mixed up through a coprecipitation method to prepare a supramolecular complex to provide physical insights into the formation and stability of the inclusion complex (IC). The prepared hybrid was characterized by (1)H nuclear magnetic resonance ((1)H NMR), Fourier transform infrared (FTIR) spectroscopy, electrospray ionization (ESI) mass spectrometry, DSC, and fluorescence spectroscopic studies. Job’s plot provides a stoichiometric ratio of 1:1 and the Benesi–Hildebrand double reciprocal plot gives binding constant values using fluorescence spectroscopic titrations and the ESI mass data support the experimental observations. The results of molecular modeling were systematically analyzed to validate the inclusion complexation. In preliminary computational screening, α-cyclodextrin IC of umbelliferone was found to be quite stable based on the docking score, binding free energies, and dynamic simulations. In addition, the results obtained from (1)H NMR and FTIR spectroscopy studies supported the inclusion complexation phenomenon. The results obtained from computational studies were found to be consistent with the experimental data to ascertain the encapsulation of umbelliferone into α-cyclodextrin. |
format | Online Article Text |
id | pubmed-7689913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-76899132020-11-27 Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body Roy, Niloy Ghosh, Biswajit Roy, Debadrita Bhaumik, Biswajit Roy, Mahendra Nath ACS Omega [Image: see text] In this study, umbelliferone and α-cyclodextrin host molecules have been mixed up through a coprecipitation method to prepare a supramolecular complex to provide physical insights into the formation and stability of the inclusion complex (IC). The prepared hybrid was characterized by (1)H nuclear magnetic resonance ((1)H NMR), Fourier transform infrared (FTIR) spectroscopy, electrospray ionization (ESI) mass spectrometry, DSC, and fluorescence spectroscopic studies. Job’s plot provides a stoichiometric ratio of 1:1 and the Benesi–Hildebrand double reciprocal plot gives binding constant values using fluorescence spectroscopic titrations and the ESI mass data support the experimental observations. The results of molecular modeling were systematically analyzed to validate the inclusion complexation. In preliminary computational screening, α-cyclodextrin IC of umbelliferone was found to be quite stable based on the docking score, binding free energies, and dynamic simulations. In addition, the results obtained from (1)H NMR and FTIR spectroscopy studies supported the inclusion complexation phenomenon. The results obtained from computational studies were found to be consistent with the experimental data to ascertain the encapsulation of umbelliferone into α-cyclodextrin. American Chemical Society 2020-11-13 /pmc/articles/PMC7689913/ /pubmed/33251458 http://dx.doi.org/10.1021/acsomega.0c04716 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes. |
spellingShingle | Roy, Niloy Ghosh, Biswajit Roy, Debadrita Bhaumik, Biswajit Roy, Mahendra Nath Exploring the Inclusion Complex of a Drug (Umbelliferone) with α-Cyclodextrin Optimized by Molecular Docking and Increasing Bioavailability with Minimizing the Doses in Human Body |
title | Exploring the Inclusion Complex of a Drug (Umbelliferone)
with α-Cyclodextrin Optimized by Molecular Docking and
Increasing Bioavailability with Minimizing the Doses in Human Body |
title_full | Exploring the Inclusion Complex of a Drug (Umbelliferone)
with α-Cyclodextrin Optimized by Molecular Docking and
Increasing Bioavailability with Minimizing the Doses in Human Body |
title_fullStr | Exploring the Inclusion Complex of a Drug (Umbelliferone)
with α-Cyclodextrin Optimized by Molecular Docking and
Increasing Bioavailability with Minimizing the Doses in Human Body |
title_full_unstemmed | Exploring the Inclusion Complex of a Drug (Umbelliferone)
with α-Cyclodextrin Optimized by Molecular Docking and
Increasing Bioavailability with Minimizing the Doses in Human Body |
title_short | Exploring the Inclusion Complex of a Drug (Umbelliferone)
with α-Cyclodextrin Optimized by Molecular Docking and
Increasing Bioavailability with Minimizing the Doses in Human Body |
title_sort | exploring the inclusion complex of a drug (umbelliferone)
with α-cyclodextrin optimized by molecular docking and
increasing bioavailability with minimizing the doses in human body |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689913/ https://www.ncbi.nlm.nih.gov/pubmed/33251458 http://dx.doi.org/10.1021/acsomega.0c04716 |
work_keys_str_mv | AT royniloy exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody AT ghoshbiswajit exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody AT roydebadrita exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody AT bhaumikbiswajit exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody AT roymahendranath exploringtheinclusioncomplexofadrugumbelliferonewithacyclodextrinoptimizedbymoleculardockingandincreasingbioavailabilitywithminimizingthedosesinhumanbody |